PsiQuantum Partners with National Cancer Center Japan to Advance Quantum Computing in Drug Discovery
核心洞察
PsiQuantum (搜索) has signed a collaborative research agreement with the National Cancer Center Japan (搜索) to advance quantum computing applications in oncology and healthcare drug discovery.
The partnership will focus on developing fault-tolerant quantum algorithms and clinically relevant quantum applications using PsiQuantum (搜索)'s Construct (搜索) software platform.
Utility-scale quantum computers promise to accelerate drug discovery by simulating molecular systems with unprecedented accuracy, potentially reducing research and development costs and time-to-market for new treatments.
PsiQuantum (搜索) announced on March 12, 2026, that it has signed a collaborative research agreement with the National Cancer Center Japan (搜索) to advance applications in oncology and healthcare for utility-scale quantum computers. The partnership represents a significant step toward leveraging quantum computing technology to address pressing challenges in pharmaceutical research and development.
Strategic Collaboration Framework
Under the newly formed collaboration, PsiQuantum (搜索) will work alongside the National Cancer Center Japan (搜索) to advance fault-tolerant quantum algorithm development and collaborate with other leading pharmaceutical companies in Japan in developing clinically relevant quantum applications. The partnership will utilize PsiQuantum's software suite, Construct (搜索)—a secure, end-to-end platform for designing, analyzing, and optimizing algorithms for fault-tolerant quantum computing.
"PsiQuantum (搜索) is proud to work alongside the National Cancer Center Japan (搜索) as we explore what utility-scale quantum computing will be able to deliver in designing new treatments for the benefit of researchers and patients," said Sam Pallister, PsiQuantum's Vice President for Quantum Applications. "Once deployed, utility-scale quantum computers will accelerate research and development that transforms how we develop new medicines—and partnerships like these are critical for making sure providers are equipped to take full advantage of this technology."
Addressing Current R&D Limitations
The research and development process for new pharmaceutical treatments is currently long and expensive, with traditional computing methods struggling to produce meaningful or reliable outcomes that expedite a treatment's time-to-market. This collaboration aims to address these fundamental challenges through quantum computing applications.
Dr. Takayuki Yoshino, Director for the Department of Global Oncology at the National Cancer Center Hospital East in Kashiwa, Japan, expressed enthusiasm for the partnership: "We are thrilled to partner with PsiQuantum (搜索) on leveraging quantum computing technology to address some of the most pressing challenges in healthcare. Together, our teams are poised to conduct innovative research and unlock new solutions at the intersection of pharmaceuticals, biotechnology, and quantum computing."
Quantum Computing's Transformative Potential
Utility-scale quantum computers promise to deliver transformative results across the healthcare industry by simulating molecular systems with unprecedented accuracy, scale, and speed. By executing chemically accurate simulations faster, fault-tolerant quantum computers can accelerate drug discovery, lower research and development costs, and help providers tackle real-world healthcare challenges.
The agreement underscores the enormous potential for utility-scale quantum computing across the healthcare value chain, specifically in research and development, resource allocation, and patient outcomes in cancer treatment. This partnership positions both organizations at the forefront of integrating advanced quantum computing technologies into practical healthcare applications.